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For	many	years	mononuclear	phagocyte	system	was	
known	as	dynamic	network	with	functionally	heteroge-
neous	scavenger	cells	of	 the	monocyte/macrophage	
lineage,	which	are	extremely	critical	for	the	integrity	of	
host	defense.	During	last	two	decades,	it	has	become	
apparent	 that	macrophages	(Mφs)	express	complex	
functions	such	as	phagocytosis,	antigen	presentation,	
production	of	cytokines	capable	 to	modulate	 the	re-
sponses	of	other	immune	system	cells	and	themselves	
as	well,	and	bactericidal/tumoricidal	activities	 [1–4].	
Activated	Mφs	can	kill	some	tumor	cells	directly	or	elicit	
tumor-destructive	reactions,	also	they	are	able	to	stimu-
late	antitumor	cytotoxic	lymphocytes	[4].	Macrophage-
mediated	killing	of	tumor	cells	can	be	realized	through	
different	processes	that	can	involve	release	of	soluble	
factors	(i.e.,	tumor	necrosis	factor-α	(TNF-α),	lysosomal	
enzymes,	reactive	oxygen	species	(ROS)	and	nitric	oxide	
(NO)	etc.)	[2,	3,	5],	activation	of	antibody-dependent	
cell-mediated	cytotoxicity	and	phagocytosis	[6].
ROS	and	NO	are	key	elements	 in	 antimicrobial	
and	antitumor	macrophage-mediated	host	defense,	
at	 the	same	 time	 they	play	a	complex	 role	 in	many	
diseases	and	in	metabolic	regulation	[6,	7].	Under	nor-
mal	conditions,	the	integrity	of	this	complex	process	
is	maintained,	but	during	 tumor	progression	 these	
mechanisms	may	become	altered,	 resulting	 in	 the	
inability	of	Mφs	to	lyse	tumor	cells	[8].
The	activation	of	Mφs	tumoricidal	activity	is	complex	
process	that	can	be	induced	with	different	bacterial	cell	
substances,	including	LPS	and	cytokines,	such	as	IFN-
γ	[9,	10].	Bacterial	DNA	and	synthetic	oligonucleotides	
containing	unmethylated	CpG	motifs	are	now	recognized	
as	potent	 immunostimulants	[11–13].	Many	 investiga-
tions	showed	that	CpG	DNA	is	detected	by	majority	of	
innate	immune	system	cells,	in	particular	dendritic	cells,	
Mφs,	and	also	B	cells	[11,	14].	In	murine	Mφs/monocytes	
CpG	DNA	causes	the	direct	activation	of	nuclear	factor	
κB	(NFκB)	and	initiation	of	cytokine	expression	includ-
ing	TNF-α	[15].	Yi	et	al.	[16]	have	shown	that	leukocytes	
respond	to	CpG	DNA	through	novel	pathway	involving	
the	pH-dependent	generation	of	 intracellular	ROS,	
which	is	essential	for	the	activation	of	NFκB	and	all	the	
downstream	events	observed	after	CpG	DNA	stimulation.	
However,	Mφs	expression	of	the	inducible	NO	synthase	
and	production	of	NO	in	response	to	CpG	DNA	is	not	
direct	but	requires	IFN-γ	priming	[17].
Pleiotropic	 immunostimulatory	activity	of	CpG	DNA	
provides	a	unique	opportunity	to	design	new	immuno-
therapeutic	approaches	for	 treatment	of	cancer	[18].	
CpG	DNA	can	be	successfully	used	alone	to	locally	ac-
tivate	the	innate	 immunity	and	trigger	a	tumor-specific	
response	or	be	applied	in	combination	with	different	vac-
cines	and	monoclonal	antibodies	[11,	13,	19].
The	goal	of	the	present	work	is	to	study	influence	of	
bacterial	CpG	DNA	(bCpG	DNA)	in vitro	and	in vivo	on	
superoxide	anion	(SOA)	and	NO	production	by	perito-
neal	Mφs	(PMφs)	of	normal	and	tumor-bearing	mice.	
MATERIALS AND METHODS
Animals and reagents. BALB/c	mice	(9–12	weeks)	
were	obtained	from	vivarium	of	R.E.	Kavetsky	Institute	
of	Experimental	Pathology,	Oncology	and	Radiobiology,	
NAS	of	Ukraine	(Kyiv,	Ukraine).	Animals	were	housed	in	
standard	facilities,	with	water	and	food	ad libitum.	All	
animals	were	maintained	under	strict	ethical	conditions	
according	to	International	recommendations.
Hydroxylamine-2,2,6,6-tetramethyl-4-oxypiperi-
dine	was	obtained	from	Institute	of	Chemical	Physics,	
RAS,	Russia.
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Bacterial strains and tumor models. Bacillus 
subtilis strain	GP1-807-03	stored	as	strain	IMB	B-7108	
in	Bacterial	Strain	Collection	of	D.K.	Zabolotny	Institute	
of	Microbiology	and	Virology,	NAS	of	Ukraine	 (Kyiv,	
Ukraine)	was	used. Bacillus subtilis GP1-807-03	was	
routinely	isolated	from	soil	samples,	characterized	and	
cultivated	in	beef-extract	broth	(pH	7.0)	at	37	°C	during	
8	days	with	moderate	shaking	(120	rpm).
In	the	study	Ehrlich	carcinoma	strain	obtained	from	
the	National	Bank	of	Cell	Lines	and	Tumor	Strains	of	
R.E.	Kavetsky	Institute	of	Experimental	Pathology,	Onco-
logy	and	Radiobiology	NAS	of	Ukraine	(Kyiv,	Ukraine)	
was	used.	For	tumor	transplantation,	2.5	×	105	Ehrlich	
carcinoma	cells	in	a	volume	of	100	μl	of	Hanks`	balanced	
salt	solution	(HBSS,	Sigma,	USA)	were	inoculated	sub-
cutaneously	(s.c.)	into	right	flank	of	BALB/c	mice.
Preparation and analysis of bacterial DNA.	Bac-
terial	extracellular	DNA	was	isolated	from B. subtilis 
GP1-807-03	culture	medium	on	9th	day	of	cultivation	
according	to	[20].
Polyacrylamide	gel	(PAAG)	electrophoresis	was	used	
for	identification	of	DNA	fragments	in	the	samples	[21].	To	
detect	the	presence	of	unmethylated	CG-dinucleotides,	
restriction	analysis	of	DNA	with	endonuclease	Hpa	 II	
(Sigma,	USA)	[22]	was	applied	with	the	next	PAAG	electro-
phoresis	followed	by	ethidium	bromide	staining	[21].	Re-
striction	endonuclease	digestion	of	DNA	was	performed	
according	to	the	instructions	of	the	manufacturer.
Isolated	DNA	was	dissolved	in	0.15	M	endotoxin	free	
phosphate	buffer	saline	(PBS)	at	concentration	1	mg/ml.	
Samples	of	prepared	DNA	were	stored	at	–20	°С.	Re-
peated	freezing	of	DNA	samples	was	avoided.
Mice treatment. Two	main	groups	of	BALB/c	mice	
(with	s.c.	 transplanted	Ehrlich	carcinoma	or	without	
tumor)	were	used	in	the	study.	Normal	mice	(without	
tumor)	received	single	s.c.	 injection	of	bCpG	DNA	at	
dose	of	0.25	and	2.5	mg/kg	body	weight.	Tumor-bear-
ing	mice	were	similarly	injected	with	CpG	DNA	into	site	
of	 tumor	cell	 inoculation	 (on	 the	2nd	day	after	 tumor	
transplantation)	or	directly	close	to	the	tumor	(on	the	
8th	day	after	tumor	transplantation).	Control	normal	or/
and	tumor-bearing	mice	received	injections	with	PBS.
On	 the	10th	day	after	experiment	beginning,	all	
mice	were	sacrificed	and	peritoneal	lavage	fluids	were	
collected.	Tumors	of	all	mice	were	stripped	out	and	
weighed	accurately	with	torsion	balance.
Preparation and stimulation of PMφs. Peritoneal	
lavage	fluid	cells	were	obtained	from	peritoneal	cavity	
of	immunized	by	CpG	DNA	or	non-immunized	normal	
and	tumor-bearing	mice.	Purified	PMφs	were	obtained	
from	pooled	peritoneal	lavage	fluid	cells	according	to	
[23].	All	cell	samples	were	counted,	adjusted	in	RPMI	
1640	(Sigma,	USA),	supplemented	with	2%	FBS	(Gib-
co,	USA)	to	1	×	106	cells/ml,	and	preincubated	for	2	h.	
Before	and	after	each	experiment	cellular	viability	was	
routinely	measured	by	the	trypan	blue	exclusion	test.	In	
all	cases	the	viability	was	higher	than	95%.	For	in vitro	
experiments,	bCpG	DNA	(2	and	20	μg/ml)	was	added	
to	respective	PMφ	samples	and	incubated	for	2,	10,	
20	and	30	min	at	37	°C	in	a	humidified	atmosphere	of	
5%	CO2	with	moderate	shaking	(100	rpm).
Electron paramagnetic resonance (EPR) 
spectroscopy. Electron	paramagnetic	 resonance	
(EPR)	spin-trapping	technique	was	used	to	study	SOA	
and	NO	production	by	PMφs	[24,	25].	EPR	spectra	of	
liquid	samples	were	recorded	using	an	EPR	spectrome-
ter	(RE	1307,	Russia).
SOA generation analysis.	Spin	trapping	measure-
ments	of	SOA	produced	by	PMφs	were	performed	using	
hydroxylamine-2,2,6,6-tetramethyl-4-oxypiperidine.	For	
recording	at	20	°C,	the	sample	was	placed	into	a	special	
custom-made	quartz	cavitiy	(volume	170	μl)	[24].	Briefly,	
100	μl	aliquots	of	PMφs	suspension	were	mixed	with	100	
μl	of	reaction	buffer	(2	×	10-3	mol/l	hydroxylamine,	2	×	
10-3	mol/l	NADP·H	in	phosphate	buffer,	pH	7.4	with	5	×	
10-4	mol/l	diethyltryaminepentaacetic	acid).	Estimations	
of	SOA	production	were	performed	three	times	with	a	
1	min	interval.	The	obtained	data	were	expressed	as	SOA	
generation	rate	and	measured	as	nmoles	of	produced	
SOA	per	8.5	×	104	PMφs	per	min.
NO assay.	The	presence	of	NO	in	PMφs	suspen-
sion	was	determined	using	diethyldithiocarbamate	
(DEDTC;	Sigma,	USA).	Briefly,	aliquots	of	500	μl	of	PMφs	
suspension	were	mixed	with	100	μl	of	reaction	buffer	
(PBS,	pH	7.4	with	Fe2+	ions),	placed	into	special	metal	
molding	tools	and	have	been	frozen	in	liquid	nitrogen.	Re-
gistration	of	NO	was	performed	in	Quartz	Dewar	(Brucker)	
cuvette	at	—	196	°C.	The	obtained	data	were	expressed	as	
nmoles	of	produced	NO	per	5	×	105	PMφs.
Statistical analysis.	 Data	 are	 expressed	 as	
means	±	standard	error	of	mean.	For	 in vivo experi-
ments,	each	group	consisted	of	six	mice.	Each	experi-
ment	was	repeated	at	least	twice.	Dunnett	multiple	com-
parisons	 test	and	Student-Newman-Keuls	 test	were	
used	to	comparisons	of	obtained	data.	Values	p	<	0.05	
were	considered	as	significant.	Statistical	analysis	was	
performed	using	GraphPad	InStat.
RESULTS AND DISCUSSION
Peculiarities of in vitro metabolic activation 
of PMφs by bCpG DNA.	To	evaluate	 the	metabolic	
activity	of	murine	PMφs,	EPR	spectroscopy	was	used	
to	directly	measure	SOA	and	NO	with	respective	spin	
traps.	For	this	purpose,	suspensions	of	PMφs	obtained	
from	peritoneal	cavities	of	normal	and	tumor-bearing	
mice	were	stimulated	in	different	expositions	with	2	or	
10	μg/ml	CpG	DNA	from	culture	medium	of	B. subtilis.	
As	shown	in	Fig.	1,	incubation	of	PMφs	with	bCpG	DNA	
was	immediately	reflected	on	their	capability	to	gener-
ate	SOA.	However,	this	effect	depended	on	bCpG	DNA	
concentration	and	exposure	time.
PMφs	of	normal	mice	 responded	 to	bCpG	DNA	
stimulation	 as	 early	 as	 after	 2	min	 of	 incubation	
(see	Fig.	1,	a).	When	2	μg/ml	bCpG	DNA	was	added,	
the	SOA	generation	rate	of	stimulated	PMφs	rapidly	
increased	by	2.5-fold	(p <	0.01)	and	dramatically	de-
creased	 (almost	 3.5-fold),	when	concentration	of	
bCpG	DNA	was	10	μg/ml	(absolute	values	were	1.25	
and	0.15	nM/min,	 respectively,	versus	 0.5	nM/min	
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in	 control).	 After	 10	min	 incubation	of	PMφs	with	
bCpG	DNA,	opposite	effect	on	SOA	generation	was	
observed.	Drastic	drop	 in	SOA	generation	 rate	 (to	
the	 level	of	0.25	nM/min)	was	 registered	 in	PMφs	
stimulated	by	2	μg/ml	bCpG	DNA,	whereas	10	μg/ml	
bCpG	DNA	 led	 to	extremely	 rapid	 increase	of	SOA	
generation	rate	to	2.15	nM/min	(higher	than	14-fold	as	
compared	with	previous	value,	p <	0.01).	Subsequent	
responses	of	PMφs	on	stimulation	with	2	μg/ml	bCpG	
DNA	during	20	and	30	min	 incubation	were	similar	
to	previous	observations	(see	Fig.	1,	a).	High	bCpG	
DNA	concentration	(10	μg/ml)	caused	rapid	decrease	
of	SOA	generation	rate	to	control	level	(after	20	min	
incubation),	and	after	30	min	 incubation	 the	values	
were	lower	than	in	control	and	averaged	0.3	nM/min.	
Thus,	after	30	min	incubation	with	bCpG	DNA	PMφs	of	
normal	mice	in	fact	have	use	all	resources	for	genera-
tion	and	release	of	SOA.
Fig. 1. Effect	in vitro	of	bacterial	CpG	DNA	on	generation	of	SOA	
by	PMφs	of	normal	(a)	and	tumor-bearing	(b)	mice
*p < 0.05,	**p <	0.01	compared	to	control
PMφs	of	tumor-bearing	mice	responded	on	bCpG	
DNA	stimulation	at	different	 rate	 than	PMφs	 from	
normal	mice	(see	Fig.	1,	b).	It	is	important	to	note	that	
unstimulated	PMφs	 from	mice	with	 tumors	showed	
very	weak	capability	to	generate	SOA.	The	SOA	gen-
eration	rate	of	PMφs	from	control	tumor-bearing	mice	
was	0.1	nM/min	—	5-fold	 lower	 than	 that	 in	control	
normal	mice	PMφs	(see	Fig.	1,	a,	b).	Stimulation	of	
tumor-bearing	mice	PMφs	with	2	μg/ml	bCpG	DNA	
weakly	activated	PMφs	with	insignificant	differences	
in	 temporal	characteristics	 (Fig.	1,	b).	When	PMφs	
of	tumor-bearing	mice	were	stimulated	by	10	μg/ml	
bCpG	DNA,	 fluent	 increase	of	SOA	generation	 rate	
with	peak	(1.6	versus	0.1	nM/s	in	control)	after	30	min	
incubation	was	observed.
Thus,	 the	highest	values	of	SOA	generation	 rate	
by	PMφs	were	achieved	with	application	of	10	μg/ml	
bCpG	DNA	after	10	min	stimulation	for	PMφs	of	normal	
mice	(4.3-fold	higher	comparing	with	control)	and	after	
30	min	stimulation	(16-fold	higher	than	in	control)	for	
PMφs	of	tumor-bearing	mice.
Levels	of	NO	production	by	murine	PMφs	are	showed	
on	Fig.	2.	The	same	pattern	was	observed	with	NO	pro-
duction	and	SOA	generation	by	normal	mice	PMφs	 in 
vitro	stimulated	with	bCpG	DNA	(see	Fig.	1,	a,	Fig.	2,	a).	
Incubation	of	PMφs	with	2	μg/ml	of	bCpG	DNA	caused	
a	minimal	activation	but	with	marked	 inhibition	 in	NO	
production	(Fig.	2,	a).	After	a	10	min	exposure	to	10	μg/ml	
bCpG	DNA,	PMφs	developed	the	highest	activity	(2.7	
nM/5	×	105	cells,	p <	0.01)	and	subsequent	gradual	
decrease	in	NO	production	was	observed.	So,	dramatic	
decrease	of	NO	production	by	PMφs	stimulated	during	
30	min	with	10	μg/ml	bCpG	DNA	was	shown,	evidencing	
on	rapid	depletion	of	PMφ	ability	to	generate	and	release	
NO.	Along	with	that,	NO	production	by	PMφs	stimulated	
with	2	μg/ml	bCpG	DNA	had	oscillatory	character	with	
gradual	increase	of	NO	levels	(see	Fig.	2,	a).
Fig. 2. Effect	in vitro	of	bacterial	CpG	DNA	on	NO	production	by	
PMφs	of	normal	(a)	and	tumor-bearing	(b)	mice
*p < 0.05,	**p <	0.01	compared	to	control
Fig.	2,	b	 compares	 the	 time	course	stimulation	
of	 PMφs	of	 tumor-bearing	mice.	Bacterial	 bCpG	
DNA	at	concentration	of	2	μg/ml	stimulated	 in vitro	
NO	production	by	PMφs	 insufficiently	during	all	 the	
time	of	incubation.	Nevertheless,	already	after	2	min	
incubation	NO	 levels	were	 significantly	 increased	
(1.6-fold,	p <	0.01)	compared	to	control.	At	first,	treat-
ment	of	PMφs	by	higher	concentration	of	bCpG	DNA	
(10	μg/ml)	weakly	but	significantly	stimulated	capabili-
ty	to	produce	of	NO	(0.94	nmol/5	×	105	cells	after	2	min	
incubation,	p <	0.01)	and	after	30	min	incubation	NO	
production	values	were	close	to	control	ones.
Thus,	effects	of	bCpG	DNA	stimulation	 in vitro	on	
metabolic	activity	of	PMφs	depended	on	concentration	
and	period	of	exposure	to	bCpG	DNA.	Higher	concen-
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tration	of	bCpG	DNA	caused	strong	metabolic	activa-
tion	of	PMφs	of	normal	mice	as	early	as	after	10	min	
stimulation	and	resulted	in	subsequent	anergy	of	PMφs	
displayed	in	dramatic	inability	to	generate	and	release	
SOA	and	NO.	Tumor	growth	was	also	notably	reflected	
in	bCpG	DNA-induced	metabolic	activation	of	PMφs.	
Response	of	tumor-bearing	mice	PMφs	on	bCpG	DNA	
treatment	was	slow	and	characterized	by	gradual	en-
hancement	or	extinction	of	metabolic	activity.
Effects of bCpG DNA administration in vivo on 
metabolic activity of murine PMφs.	To	evaluate	pos-
sible	effects	of	in vivo	bCpG	DNA	application	on	metabolic	
activity	of	murine	PMφs,	normal	and	tumor-bearing	mice	
were	s.c.	immunized	with	single	injection	of	bCpG	DNA	
at	the	doses	of	0.25	and	2.5	mg/kg	of	body	weight.	To	
assess	capability	of	bCpG	DNA	to	activate	PMφs	in	mice	
with	different	stages	of	tumor	growth,	immunization	was	
performed	at	2nd	and	8th	days	after	tumor	cell	inoculation.	
Metabolic	activity	of	PMφs	of	normal	mice	was	analyzed	
at	2nd	and	8th	days	after	immunization	in	order	to	evaluate	
duration	of	bCpG	DNA	stimulatory	effects.
Total	number	of	peritoneal	lavage	fluid	cells	obtained	
from	peritoneal	cavities	of	normal	or	tumor-bearing	mice	
at	different	times	after	s.c.	injection	of	a	single	dose	of	
bCpG	DNA	was	not	significantly	changed	as	compared	
to	respective	controls,	except	for	statistically	significant	
increase	of	total	cellularity	(p <	0.05)	at	8th	day	of	obser-
vation	in	normal	mice	injected	by	bCpG	DNA	at	a	dose	of	
0.25	mg/kg	of	body	weight	(Table).	Our	previous	studies	
also	did	not	show	any	significant	changes	in	cell	content	
of	peritoneal	lavage	fluid	after	s.c.	injection	with	bCpG	
DNA	at	a	dose	of	5	mg/kg	body	weight	(approximately	
100	μg/mouse),	whereas	intraperitoneally	injected	mice	
developed	strong	inflammatory	response	determined	as	
a	transitory	aseptic	peritonitis	[27].
Table. Effect of bacterial CpG DNA administration on cellularity of perito-
neal lavage fluid of immunized mice
Group 
of mice
Day of CpG DNA 
injection
Dose of CpG 
DNA, mg/kg
Total number of peri-
toneal lavage fluid 
cells (× 106/mice)
mice without 
tumors
2nd 0.25 13.1 ± 3.4
2.5 12.3 ± 3.2
8th 0.25 14.1 ± 1.7*
2.5 10.3 ± 1.7
control – 9.6 ± 1.3
mice with 
tumors
2nd 0.25 12.7 ± 5.3
2.5 7.9 ± 3.6
8th 0.25 9.5 ± 2.8
2.5 10.8 ± 0.5
control – 9.2 ± 1.0
*p < 0.05 compared to respective control
As	 shown	 in	 Fig.	 3,	 a,	 in	 response	 to	 stimula-
tion	with	 bCpG	DNA,	 PMφs	 of	 normal	mice	 dis-
played	no	significantly	 increased	capacity	 to	gener-
ate	and	 release	of	SOA	as	compared	with	control.	
Only	at	 the	8th	day	after	challenge	with	bCpG	DNA	
(0.25	mg/kg	of	body	weight)	the	modest	and	statistically	
significant	elevation	of	SOA	production	was	observed	
(0.8	versus	0.45	nM/min	 in	control,	p <	0.05).	These	
observations	indicate	that	in vivo	application	of	relatively	
low	doses	of	bCpG	DNA	(0.25–2.5	mg/kg	body	weight)	
results	 in	actually	 insignificant	capability	of	PMφs	to	
generate	and	produce	ROS	including	SOA	at	least	during	
8	days	after	immunization.
PMφs	of	control	tumor-bearing	mice	in	fact	showed	
very	weak	activity	 in	SOA	production	 (Fig.	3,	b).	 In	
contrast,	PMφs	obtained	 from	 tumor-bearing	mice	
injected	by	bCpG	DNA	at	the	2nd	day	after	tumor	cell	
inoculation	were	able	 to	generate	SOA	and	demon-
strated	most	evident	increase	in	SOA	generation	rate	
(0.3–0.5	compared	 to	0.15	nmol/min	 in	control).	 If	
tumor-bearing	mice	were	injected	with	bCpG	DNA	at	
the	8th	day	after	tumor	transplantation,	no	increase	in	
ability	of	SOA	generation	by	PMφs	was	observed.
Fig. 3. Effect	of	bacterial	CpG	DNA	administration	on	SOA	genera-
tion	rate	by	PMφs	of	normal	(a)	and	tumor-bearing	(b)	mice	
*p < 0.05,	**p <	0.01	compared	to	control
Application	of	bCpG	DNA	 in	normal	mice	had	a	
marked	dose-dependent	effect	on	NO	production	by	
PMφs	(Fig.	4,	a).	Administration	of	bCpG	DNA	at	a	dose	
of	0.25	mg/kg	body	weight	resulted	in	significant	increase	
of	NO	production	that	averaged	3.7	(p <	0.01)	and	1.94	nM	
at	the	2nd	and	8th	days	after	bCpG	DNA	challenge,	respec-
tively,	whereas	in	control	group	—	only	1.45	nM.	As	shown	
in	Fig.	4,	a,	injection	of	bCpG	DNA	(2.5	mg/kg	body	weight	
caused)	resulted	in	marked	inhibition	of	NO	production	by	
PMφs	(0.82	and	1.1	nM	versus	1.45	nM	in	control)	at	both	
days	of	observation.
PMφs	from	tumor-bearing	mice	after	challenge	with	
bCpG	DNA	at	a	dose	of	2.5	mg/kg	body	weight	responded	
by	increased	NO	levels	as	compared	to	control	(Fig.	4,	b).	
Administration	of	bCpG	DNA	(0.25	mg/kg	body	weight)	
resulted	in	2.5-fold	increase	of	NO	levels	at	the	2nd	day	after	
tumor	transplantation	and	4-fold	increase	of	NO	produc-
tion	at	the	8th	day	after	tumor	transplantation	(p <	0.01).	
When	mice	were	injected	with	2.5	mg/kg	bCpG	DNA,	only	
2-fold	increase	of	NO	levels	was	observed	at	the	2nd	day	
after	tumor	transplantation.
Thus,	application	of	bCpG	DNA	 in vivo	 resulted	 in	
significant	changes	of	PMφs	metabolic	activity.	PMφs	of	
normal	mice	injected	with	bCpG	DNA	didn’t	show	marked	
increase	of	SOA	generation	rate,	except	that	at	the	8th	day	
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after	challenge	with	0.25	mg/kg	bCpG	DNA,	whereas	
significantly	increased	SOA-producing	activity	of	PMφs	
of	tumor-bearing	mice	was	observed	only	when	bCpG	
DNA	immunization	was	performed	at	 the	2nd	day	after	
tumor	transplantation.	Augmentation	of	NO	production	
by	PMφs	was	observed	in	normal	mice	at	the	2nd	day	and	
in	tumor-bearing	mice	-	on	both	terms	of	observations	
after	immunization	with	0.25	mg/kg	bCpG	DNA.
Fig. 4. Effect	of	bacterial	CpG	DNA	administration	on	NO	produc-
tion	by	PMφs	of	normal	(a)	tumor-bearing	(b)	mice
*p < 0.05,	**p <	0.01	compared	to	control
Next,	we	evaluated	whether	single	dose	injection	of	
bCpG	DNA	has	infuence	on	tumor	growth	in	mice	with	
solid	Ehrlich	carcinoma.	The	results	presented	in	Fig.	5	
demonstrated	that	mice	injected	with	0.25	mg/kg	bCpG	
DNA	had	smaller	tumors	compared	to	control	animals.	
If	mice	were	challenged	with	10-fold	higher	dose	bCpG	
DNA,	the	trend	to	stimulation	of	tumor	progression	was	
observed	(see	Fig.	5).	These	data	show	that	treatment	
of	mice	by	higher	doses	of	bCpG	DNA	(2.5	mg/kg	in	this	
investigation)	possibly	stimulate	tumor	growth	probably	
because	of	decreased	functional	activity	of	cells	of	im-
mune	system	(in	particular,	PMφs).
Mφs	have	the	opportunity	to	produce	SOA	and	NO	
in	nearly	equimolar	amounts	and	thus	can	be	genera-
tors	of	the	particularly	destructive	products.	Moreover,	
Adachi	et	al.	[28]	showed	that	the	highest	degrees	of	
tumor-associated	Mφs	phagocytosis	are	associated	
with	favorable	prognosis.	In	this	regard,	Fiumara	et	al.	
[29]	demonstrated	that	distant	metastases	developed	
in	none	of	the	cancer	patients	with	in situ evidence	of	
phagocytosis	of	neoplastic	cells	by	tumor-associated	
Mφs.	Baskić	et	al. [30] have	showed	that	 functional	
properties	of Mφs	isolated	from	different	anatomical	
sites	of	cancer	patients	possess	different	 functional	
properties.	 It	has	been	 found	 that	 tumor-associated	
Mφs	display	a	diminished	capacity	 to	produce	NO.	
Along	with	 this,	Brignole	et	al.	 [31]	have	presented	
evidence	that	depletion	of	Mφs	led	to	a	complete	loss	
of	antitumor	efficacy	 in	neuroblastoma-bearing	mice	
injected	with	liposome-CpG-myb-as.	Activation	of	Mφs	
is	an	attractive	approach	in	the	development	of	cancer	
immunotherapy	[32–34].	Indeed,	evidence	from	many	
studies	showed	 that	activated	Mφs	are	capable	 to	
lyse	selectively	tumor	cells	in vitro [33–36]	and	play	an	
important	role	in	the	immune-mediated	destruction	of	
tumor	in vivo [37–40].	In	clinical	studies	Mφs	are	found	
to	play	a	role	in	the	mechanism	of	the	antibody-media-
ted	tumor	killing	[41,	42].	Taken	together,	these	studies	
suggest	that	activation	of	Mφs	could	be	fine	strategy	for	
the	development	of	cancer	immunotherapy.
Fig. 5. Effect	of	single	dose	bacterial	CpG	DNA	administration	
on	Ehrlich	carcinoma	growth	in vivo
There	is	strong	evidence	that	during	tumor	progres-
sion,	complex	process	leading	to	ROS	and	NO	production	
may	become	altered,	resulting	in	the	inability	of	the	Mφs	
to	kill	tumor	cells.	It	is	well-known	that	factors	produced	by	
tumors	(transforming	growth	factor-β,	prostaglandin-E2,	
interleukin-10,	and	phosphatidyl	serine)	may	lead	to	dys-
regulaton	of	complex	tumoricidal	machinery	of	Mφs.	Fur-
thermore,	neoplastic	cells	have	the	capacity	to	impair	the	
production	of	T	cell-derived	cytokines	(e.	g.,	interferon-γ)	
important	for	activation	of	Mφs	[30,	43,	44].
The	results	presented	herein	provide	further	insight	
into	the	immunomodulatory	effects	of	bCpG	DNA	and	
perspectives	of	its	application	for	cancer	immunotherapy.	
For	better	understanding	of	immunomodulatory	activi-
ties	and	immunotherapeutical	potential	of	bCpG	DNA,	
it	is	crucial	to	elucidate	the	immune	system	reaction	on	
immunization	with	bCpG	DNA	with	a	focus	on	defense	
oriented	molecules	such	as	ROS	and	NO	produced	by	
Mφs.	In	the	present	study	we	showed	that	bCpG	DNA	can	
induce	SOA	and	NO	production	by	PMφs	in	a	dose-	and	
time-dependent	way.	Also,	it	is	important	to	note,	that	tu-
mor	growth	have	a	strong	inhibitory	effects	on	metabolic	
activity	of	both	intact	and	bCpG	DNA	stimulated	PMφs.	
These	findings	once	again	confirm	the	probability	of	in-
hibitory	influence	of	developing	tumor	on	host’s	immunity	
and	suggest	that	immunostimulatory	bCpG	DNA	may	be	
useful	 for	 immunotherapeutic	 treatment	of	malignant	
tumors.	Furthermore,	Auf	G.	et	al.	 [45]	have	showed	
that	Mφs	play	a	critical	role	in	mediating	the	CpG	DNA	
effects.	In	this	study,	activated	by	CpG	DNA	Mφs	but	not	
B	or	T	cells	caused	the	early	phase	of	tumor	rejection.	
Our	previous	 investigations	provide	the	evidence	that	
B. subtilis	culture	medium	CpG	DNA	possesses	strong	
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immunostimulatory	activity	and	can	be	applied	as	a	
potent	immunoadjuvant	[12,	27].	
Also,	it	is	important	to	emphasize	that	despite	ear-
lier	hopes	that	the	induction	of	nonspecific	immunity	
might	be	a	valuable	tool	in	the	fight	against	infectious	
diseases	and	tumors	with	the	subsequent	production	
of	 reactive	oxygen	and	nitrogen	 intermediates,	 it	 is	
now	clear	that	such	responses	can	be	extremely	dan-
gerous	unless	carefully	controlled.	Unfortunately,	an	
uncontrolled	production	of	ROS,	such	as	SOA,	cause	
vascular	endothelial	damage	and	strong	inflammatory	
reactions,	NO	can	profoundly	effect	on	blood	pressure	
and	flow,	 inhibits	platelet	adhesion	and	aggregation	
that	can	be	fatal	for	organism	[5,	46].
In	conclusion,	bCpG	DNA	can	 induce	significant	
metabolic	activation	of	PMφs	from	normal	and	tumor-
bearing	mice.	In	this	scenario,	it	is	apparent	that	adminis-
tration	of	immunostimulatory	CpG	DNA	to	a	tumor-bear-
ing	immunocompetent	host	would	result	the	metabolic	
activation	of	Mφs	along	with	other	immune	system	cells	
to	destroy	cancer	cells.	Thus,	results	obtained	may	be	
important	for	future	therapeutic	approaches	that	impli-
cate	immunostimulatory	CpG	DNA.	
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МОДУЛЯЦИЯ ПРОДУКЦИИ РФК И ОКСИДА АЗОТА 
ПЕРИТОНЕАЛЬНЫМИ МАКРОФАГАМИ В ОТВЕТ 
НА ВОЗДЕйСТВИЕ БАКТЕРИАЛЬНОй CPG ДНК
Цель: изучить особенности метаболической активации перитонеальных макрофагов (ПМФ) в ответ на воздействие, 
вызванное CpG ДНК бактериального происхождения. Методы: для исследования скорости генерирования радикальных 
форм кислорода (РФК) и продукции оксида азота (NO) ПМФ мышей линии BALB/c был применен метод электронного 
парамагнитного резонанса с использованием спиновых ловушек. Результаты: впервые в эксперименте продемонстрирована 
способность бактериальной CpG ДНК, выделенной из культуральной жидкости Bacillus subtilis GP1-807-03, повышать 
активность НАДФ∙Н-оксидазы и индуцибельной NO-синтазы ПМФ у мышей с солидной карциномой Эрлиха и интактных 
мышей. Отмечены различия в скорости генерирования супероксидных радикал-анионов и уровне продуцирования NO 
ПМФ у животных с карциномой Эрлиха по сравнению с контрольными животными, что выражалось в замедлении ответа 
на воздействие бактериальной CpG ДНК. Выявлена концентрационная и временная зависимость влияния бактериальной 
CpG ДНК in vitro на продукцию РФК и NO ПМФ. Выводы: полученные данные свидетельствуют о том, что бактериальная 
CpG ДНК обладает модулирующим влиянием на продукцию РФК и NO ПМФ in vitro и in vivo.
Ключевые слова: Bacillus subtilis, CpG ДНК, электронный парамагнитный резонанс, оксид азота, перитонеальные макрофаги, 
РФК, супероксидный анион.
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